Establishing reference values and evaluation of an in-house ferric reducing antioxidant power (FRAP) colorimetric assay in microplates

Yasemin Ustundag¹, Kagan Huysal¹, Serdar Kahvecioglu², Hakan Demirci³, Senol Yavuz⁴, Murat Sambel⁵, Dursun Unal⁶

¹Department of Clinical Laboratory, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
²Department of Nephrology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
³Department of Family Medicine, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
⁴Department of Cardiovascular Surgery, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
⁵Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.

ABSTRACT

Objectives. The total antioxidant capacity (TAC) of a sample can be measured with a ferric reducing antioxidant power (FRAP) assay. There are commercially available kits for FRAP assays, however they are more expensive than in-house kits. We aimed to evaluate a FRAP direct measurement method under our laboratory conditions using a microplate reader and establish reference values to use in future research projects. Methods. An in-house microplate adaptation of the FRAP method was evaluated. Reference values of FRAP were established for one hundred and twenty subjects aged between 25-55 years. FRAP levels were estimated in 30 serum samples with high glucose concentration, 44 hyperbiluribinemic neonatals and 16 patients receiving renal replacement therapy (RRT). Results. The mean FRAP level was 890±235 µmol/L. The median TAC level was 904 µmol/L. This method was found to be linear up to at least 2000 µmol/L. The intra- and inter-assay coefficients of variation were 2.7-6.7% and 5.3-10.1%, respectively. The mean FRAP level was lower than normal in diabetes and RRT patients and higher in hyperbiluribinemic neonatals (687±209 µmol/L, 609±250 µmol/L and 945±187 µmol/L, respectively). Conclusions. Our reference values give comparable results with the literature. This method is simple, reliable, and inexpensive. It could be used for studies of oxidative stress-related diseases.


Keywords: Total antioxidant capacity; ferric reducing antioxidant power; evaluation; reference range; microplate

Address for correspondence:
Yasemin Ustundag, MD., Bursa Yuksek Ihtisas Training and Research Hospital, Department of Clinical Laboratory, Bursaa, Turkey
E-mail: yaseminbudak2000@yahoo.com
Received: May 24, 2016; Accepted: June 20, 2016; Published Online: June 23, 2016

Copyright © 2016 by The Association of Health Research & Strategy
Introduction

Reactive oxygen species (ROS) are produced in the human body as a consequence of normal aerobic metabolism and a balance between production and inactivation is required. Excess production of ROS can lead to a situation of oxidative stress, which is responsible for many pathological processes and has an impact on the body’s aging process. Oxidative damage has been implicated in the cause of many diseases, including cardiovascular disease, diabetes, neuronal degeneration, depression, cancer and probably aging [1-3].

To protect cells against oxidative stress, certain low molecular weight antioxidant molecules, either water-soluble (e.g., ascorbic acid) or lipid-soluble (e.g., vitamin E), are present in extracellular fluids [2, 3]. The concentrations of antioxidants can be measured separately but this is not practical since their antioxidant effects are additive. The sum of endogenous and food-derived antioxidants represents the total antioxidant capacity of the extracellular fluid. The total antioxidant capacity of a sample can be measured, termed the total antioxidant capacity (TAC), which is the sum of endogenous and food-derived antioxidants [4].

Several methods have been developed to measure TAC, and the most common of these methods are the oxygen radical absorbance capacity (ORAC), ferric reducing antioxidant power (FRAP) and the total radical trapping antioxidant potential (TRAP) [5-7]. A FRAP spectrophotometric assay can be performed using the method developed by Benzie and Strain [8]. FRAP is a simple and relatively inexpensive test that measures the ability of antioxidants to reduce ferric iron. At low pH, excess FeIII in the reaction mixture is reduced to the ferrous form and color formation is directly related to the reducing ability of the sample. The results are highly reproducible over a wide concentration range [8].

A microplate adaptation of the FRAP method has been described previously [9]. There are commercially available kits for the FRAP assay, however they are more expensive than in-house kits [10, 11]. We aimed to evaluate a FRAP direct measurement method under our laboratory conditions using a microplate reader and establish reference values to use in future research projects [10, 11].

Methods

All measurements were carried out according to the tenets of the Declaration of Helsinki (2013 Brazil version) of the World Medical Association. This study was approved by the Bursa Yuksek Ihtisas Training and Research Hospital ethics committee, and all participants signed written informed consent forms before the study began.

Microplate Analysis Using Ferric Tripyridyl Triazine

The FRAP assay of Benzie and Strain is based on the principle that at low pH, the ferric tripyridyl triazine (FeIII TPTZ) complex gets reduced to the ferrous form, developing an intense blue color with a maximum absorption at 593 nm.

The FRAP reagent was prepared by mixing 300 mmol/L acetate buffer (pH-3.6), 10 mmol/L TPTZ [2,4,6-tri(2-pyridyl)-s-triazine] solution, and 20 mmol/L FeCl3 solution in a 10:1:1 ratio. All chemicals were purchased from Sigma-Aldrich Ltd. (St Louis, MO). 20 μL of sample (serum or plasma) was mixed with 300 μL of FRAP reagent; after 10 minutes of incubation at 37o C, the ferric tripyridyl triazine (FeIII-TPTZ) complex is reduced to the ferrous tripyridyl triazine (FeII-TPTZ) form in the presence of antioxidants. Absorbance was measured with a Readwell Touch Elisa plate analyzer (Robonik PVT Ltd. Mumbai, India). Known solutions of FeII (FeSO4X7H2O) in the range of 250-2000 μmol/L were used for calibration.

Method Verification Studies

Method verification studies were performed to determine if the assay fulfilled the specified requirements [12].

a) Limit of Detection

The detection limit of the method was determined by evaluating the zero calibrators 20 times. The detection limit was defined as the mean value of the zero calibrators + 3SD.

LOD=Xblank +3 (SD blank) [12, 13].

b) Limit of Blank

Limit of Blank (LoB) was the highest apparent analyte concentration expected to be found when
replicates of a sample containing no analyte were tested. LoB was estimated by measuring replicates of a blank sample and calculating the mean result and the standard deviation (SD). LoB = mean blank + 1.645(SD blank) [12, 13].

c) Linearity
Serial dilutions of the 250-2000 \(\mu\text{mol/L}\) ferric sulphate solutions were used for linearity analysis (Figure 1).

d) Precision
To evaluate the precision of the study, reproducibility was tested for both samples and standards. All four standards were run in 4 replicates for 20 days to determine the total coefficient of variation (between run) (Table 1). Also, four randomly chosen samples over three days were run in duplicate (Table 2).

e) Recovery of Serum Samples
Recovery was determined with a diluted serum sample having a known high FRAP activity and another with a lower FRAP activity and mixing them in the ratios given in Table 3. Mean recovery was determined in percent (%).

f) Reference Interval
To determine the reference interval for serum TAC, serum specimens from 120 healthy individuals (41 women, 79 men, 25–55 years old) were assayed [14]. They were on an average diet and were nonsmokers, but we have no information on their nutritional habits. Kolmogorov-Smirnov test was used

![Figure 1. Linear plot of serial dilutions of ferric sulphate solution.](image)

Table 1: Precision values for the FRAP assay. Sample; standard mean of 20 days 4 times a day

<table>
<thead>
<tr>
<th>Standard value ((\mu\text{mol/L}))</th>
<th>Mean ((\mu\text{mol/L}))</th>
<th>SD</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000 (\mu\text{mol/L})</td>
<td>1923</td>
<td>148</td>
<td>7.6</td>
</tr>
<tr>
<td>1000 (\mu\text{mol/L})</td>
<td>987</td>
<td>91</td>
<td>9.2</td>
</tr>
<tr>
<td>500 (\mu\text{mol/L})</td>
<td>489</td>
<td>59</td>
<td>12.0</td>
</tr>
<tr>
<td>250 (\mu\text{mol/L})</td>
<td>205</td>
<td>38</td>
<td>18.5</td>
</tr>
</tbody>
</table>

CV=coefficient of variation, FRAP=ferric reducing antioxidant power, SD=deviation of standard
to evaluate variance and normality of the data.

**Patients**

A total of 30 plasma samples were collected from the patients where blood glucose levels were found to be high. Diabetic patients are well known to have decreased TAC levels [15]. The level of TAC was estimated in all these 30 samples. Low TAC was also provided from chronic kidney failure patients after a renal replacement treatment session [16].

Samples of infants with neonatal icterus were selected as an indicator of high TAC levels [8]. Because it is hard to obtain neonatal serum, leftover serum samples were used for this group [17]. We did not obtain permission from the parents of neonatal patients. Because we do not have access to patients’ private information, this research, by definition, would not be human subject research and would not require informed consent from neonates or parents [18].

**Results**

In the regression analyses with ferric sulphate solutions, the $r^2$ value was 0.95, the slope was 0.94 ($p<0.001$), and the intercept was -10.45. Analytical sensitivity, which is the slope of the calibration line, was 0.94 (Figure 1).

The FRAP assay had a limit of detection of 26.1 μmol/L of antioxidant power and the limit of the blank was 17.2 μmol/L.

The intra-day assay coefficient of variation was 6.7-2.7% and the inter-day reproducibility was between 5.3-10.1% for the samples (Table 2). The intra-day assay coefficient of variation for standards was 7.6-18.5%. Recovery is given as 96.3% (see Table 3).

Human serum samples had FRAP concentrations that ranged from 419 to 1392 μmol/L, with a mean level of 890 μmol/L and showed a normal distribution (Kolmogorov-Smirnov test result, $p=0.085$) in healthy subjects.

Patient with diabetes (fasting value more than 120 mg/dL, median 167 (inter quartile range: 200) mg/dL) and chronic kidney failure patients after a renal replacement treatment session had FRAP values of 687±193 and 609±250 μmol/L, respectively. In neonatal hyperbilirubinemic patients FRAP values were high; 945±187 μmol/L.

**Discussion**

In this study, TAC levels in serum were between

---

**Table 2.** Intra-day and inter-day precision values for the FRAP assay using patient sample. Sample; human serum mean of 3 assays

<table>
<thead>
<tr>
<th>Sample</th>
<th>TAC (µmol/L)</th>
<th>Within-day</th>
<th></th>
<th>Between-day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (µmol/L)</td>
<td>SD (µmol/L)</td>
<td>CV (%)</td>
<td>Mean (µmol/L)</td>
</tr>
<tr>
<td>Sample 1</td>
<td>665</td>
<td>18</td>
<td>2.7</td>
<td>648</td>
</tr>
<tr>
<td>Sample 2</td>
<td>1081</td>
<td>41</td>
<td>3.7</td>
<td>1088</td>
</tr>
<tr>
<td>Sample 3</td>
<td>473</td>
<td>32</td>
<td>6.7</td>
<td>495</td>
</tr>
<tr>
<td>Sample 4</td>
<td>642</td>
<td>23</td>
<td>3.5</td>
<td>615</td>
</tr>
</tbody>
</table>

CV=coefficient of variation, FRAP=ferric reducing antioxidant power, SD=deviation of standard, TAC=total antioxidant capacity

**Table 3.** Recovery was determined by a diluted serum sample with a known high FRAP activity and another with a lower FRAP activity

<table>
<thead>
<tr>
<th>Low Sample</th>
<th>High Sample</th>
<th>Observed Concentration</th>
<th>Expected Concentration</th>
<th>Recovery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>80%</td>
<td>20%</td>
<td>431 µmol/L</td>
<td>439 µmol/L</td>
<td>99.0</td>
</tr>
<tr>
<td>60%</td>
<td>40%</td>
<td>522 µmol/L</td>
<td>562 µmol/L</td>
<td>92.8</td>
</tr>
<tr>
<td>40%</td>
<td>60%</td>
<td>646 µmol/L</td>
<td>688 µmol/L</td>
<td>94.1</td>
</tr>
<tr>
<td>20%</td>
<td>80%</td>
<td>806 µmol/L</td>
<td>816 µmol/L</td>
<td>98.7</td>
</tr>
</tbody>
</table>

Mean recovery 96.3

FRAP=ferric reducing antioxidant power
419 and 1392 μmol/L using the FRAP method in healthy subjects 25 to 55 years old. Whether FRAP levels varies with gender and with increase in age was not evaluated in this study. Our result is similar to the findings of Karajibani et al. [19], who reported a mean value of 789 μmol/L with a SD of 158.5 μmol/L, and Mistry et al. [10] who found a median of 741.2 μmol/L (range: 651.6-848.1) with a commercial kit (DetectX FRAP colorimetric detection assay K043-H1, Arbor Assays) in 472 healthy adult women. Benzie and Strain [8] found a plasma FRAP value of 1000±206 μmol/L in 141 apparently healthy Chinese adults and Kumar et al. [20] reported a value of 1005±203.23 μmol/L [20].

The level of oxidative indices may differ depending on the ethnicity, as observed in previous investigations [21]. The difference between studies might be associated with different diets. It is known that Mediterranean diet intervention increases plasma the total antioxidant capacity level in subjects [22, 23]. However, we did not question our study population about their eating habits.

In this study, absorbance was measured in an Elisa plate analyzer at 560 nm whereas Benzie and Strain [8] measured the absorbance at 593 nm in a spectrophotometer. As most of the Elisa plate analyzers do not have filters to measure the absorbance at 593 nm, the nearest wavelength of 560 nm was chosen in this study. Thus, the method became applicable and for the commercial Elisa kits 560 nm absorbance was determined as well [10, 11].

The linearity beyond 2000 μmol/L was not determined since none of the data from the healthy volunteers and patients was above 2000 μmol/L, and none of the results were below 288 μmol/L.

Mistry et al. [10] reported that with a commercial kit, the workable assay range was 31.25-1000 μmol/L and the inter- and intra-assay coefficients of variation were 9.3 and 4.3%, respectively. Our inter- and intra-assay coefficients of variation were higher [10].

In our study, serum FRAP values were found to be low in patients with diabetes and chronic kidney disease patients after renal replacement therapy with hemodialysis. Previous studies have revealed a significant imbalance of pro-oxidants and antioxidants in patients with CKD and diabetes [15, 16, 19, 24, 25]. It is also well known that bilirubin shows an antioxidant capacity, as in neonatal patients with increased bilirubin levels [26-28].

Conclusions

Our reference values gave results comparable to the literature. This method is simple, reliable, and inexpensive. It could be used for studies of oxidative stress-related diseases.

Conflict of interest

The authors disclosed no conflict of interest during the preparation or publication of this manuscript.

Financing

The authors disclosed that they did not receive any grant during conduction or writing of this study.

References